RxDoctor Payments Data

Jesse Rumbough

Nurse Practitioner · Panama City, FLNPI 1619371788

Payments from drug & device makers

$5,044in general payments, 2019–2025

Across 279 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$706
  • Merck$692
  • Novartis$577
  • Amgen$527
  • AstraZeneca$525
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$381
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,044100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,044 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$3,202
Medicare patients
48
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$48,501
EntrestoSacubitril/Valsartan44$39,358
FarxigaDapagliflozin Propanediol35$35,810
XareltoRivaroxaban34$33,040
Metoprolol Succinate79$1,584
Carvedilol158$1,459
Nebivolol Hcl18$1,127
Ranolazine ErRanolazine13$1,101
Atorvastatin Calcium82$1,019
ClopidogrelClopidogrel Bisulfate95$974
Losartan Potassium59$904
Digoxin32$821
Potassium Chloride32$749
Amlodipine Besylate82$585
Isosorbide Mononitrate ErIsosorbide Mononitrate33$436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$318$48,50135 claims
NovartisEntresto$577$39,35844 claims
AstraZenecaFarxiga$525$35,81035 claims
Johnson & JohnsonXarelto$257$33,04034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →